




EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH



Regulatory ICH Countries: Current Harmonization Challenges and Future Opportunities

WCBP, PlenShop workshop, 31 Jan 2018
Presented by: Peter Richardson
Head of Quality, European Medicines Agency

An agency of the European Union



ICH and other groups / stakeholders



Members & Observers / About ICH /

Current Members and Observers

As of June 2017, the ICH Association comprises the following Members and Observers:

MEMBERS

[Click here for the list](#)

Founding Regulatory Members

- EC, Europe
- FDA, US
- MHLW/PMDA, Japan

Founding Industry Members

- EFPIA
- JPMA
- PhRMA

Standing Regulatory Members

- Health Canada, Canada
- Swissmedic, Switzerland

Regulatory Members

- ANVISA, Brazil
- CFDA, China
- HSA, Singapore
- MFDS, Republic of Korea

Industry Members

- BIO
- IGBA
- WSMI

OBSERVERS

[Click here for the list](#)

Standing Observers

- IFPMA
- WHO

Legislative or Administrative Authorities

- CDSCO, India
- CECMED, Cuba
- COFEPRIS, Mexico
- INVIMA, Colombia
- MCC, South Africa
- National Center, Kazakhstan
- Roszdravnadzor, Russia
- TFDA, Chinese Taipei
- TGA, Australia

Regional Harmonisation Initiatives (RHIs)


- APEC
- ASEAN
- EAC
- GHC
- PANDRH
- SADC

International Pharmaceutical Industry Organisation

- APIC

International Organisation regulated or affected by ICH Guideline(s)

- Bill & Melinda Gates Foundation
- CIOMS
- EDQM
- IPEC
- PIC/S
- USP



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH



Government / Agencies

WHO

Pharmacopoeia

Trade Associations

Harmonisation Centres

Consortia

Standards Bodies



Quality Topics 2018, Possible Approaches

ICH Q12 (ongoing)

continuous manufacturing (* new),

extractables and leachables (new),

analytical methods /ICH Q2 (* new),

oligonucleotides (new),

excipient standards (new),

QOS (* 2017),

{ * from Quality Vision - Reflection Paper }

Can be many
existing sources,
e.g. E&L:



Other possible means
to deliver guidance



Regulators: Uni-Multilateral

EUROPEAN MEDICINES AGENCY

Cluster activities / Ad hoc: Technology Group

The European Medicines Agency (EMA) holds regular meetings by phone or videoconference with other non-EU regulators in so-called 'clusters'. The clusters are areas of cooperation focusing on special topics and therapeutic areas identified as requiring an intensified exchange of information and collaboration.

i-p-r-f.org
International Pharmaceutical
Regulators Forum
(now: IPRP)





Thank you

Peter Richardson,



Head of Quality Office

Specialised Scientific Disciplines Department, EMA

peter.richardson@ema.europa.eu

